Clinical Outcomes and Prognosis in Atypical Fibroxanthoma: A Systematic Review and Meta-Analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Atypical fibroxanthoma (AFX) has a low recurrence rate of 4.73% when diagnosed using strict criteria. This reinforces its generally benign nature, emphasizing accurate diagnosis for good patient prognosis.
Area Of Science
- Dermatology
- Oncology
- Pathology
Background
- Atypical fibroxanthoma (AFX) is a rare dermal spindle-cell neoplasm.
- Accurate diagnosis, prognosis, and management of AFX remain challenging.
- Existing literature lacks comprehensive analysis of AFX recurrence and prognostic factors.
Purpose Of The Study
- To evaluate local recurrence rates in AFX.
- To identify prognostic factors influencing AFX outcomes.
- To provide evidence-based insights for AFX management.
Main Methods
- Systematic review and meta-analysis of observational studies (2002-2024).
- Searched PubMed, Embase, Web of Science, and Cochrane databases.
- Analyzed recurrence rates and prognostic factors using random-effects models.
Main Results
- Included 8 studies with 1366 patients; predominantly elderly males with head/neck lesions.
- Pooled local recurrence rate was 4.73% (CI: 2.24-9.73%).
- Metastasis rate was 0.59%, with 0% disease-specific mortality.
Conclusions
- Strict adherence to diagnostic criteria yields low AFX recurrence rates.
- AFX exhibits predominantly benign clinical behavior.
- Maintaining rigorous diagnostic standards is crucial for accurate AFX prognosis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
